• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

跨性别脑磁共振成像特征与脑脊液阿尔茨海默病生物标志物

Brain MRI signatures across sex and CSF Alzheimer's disease biomarkers.

作者信息

Cheng You, He Yingnan, Gopinath Karthik, Billot Benjamin, Iglesias Juan Eugenio, Wu Chao-Yi, Dodge Hiroko, Wills Anne-Marie, Carlyle Becky, Kivisäkk Pia, Hyman Bradley T, Arnold Steven E, Das Sudeshna

机构信息

Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.

Department of Neurology, Harvard Medical School, Boston, MA 02114, USA.

出版信息

Brain Commun. 2025 May 30;7(3):fcaf210. doi: 10.1093/braincomms/fcaf210. eCollection 2025.

DOI:10.1093/braincomms/fcaf210
PMID:40503330
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12152538/
Abstract

The relationship between cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease and neurodegenerative effects is not fully understood. This study investigates neurodegeneration patterns across CSF Alzheimer's disease biomarker groups, the association of brain volumes with CSF amyloid and tau status and sex differences in these relationships in a clinical neurology sample. MRI and CSF Alzheimer's disease biomarkers data were analysed in 306 patients of the Mass General Brigham healthcare system aged 50+ (mean age = 68.4 ± 8.8 years; 43.1% female), who had lumbar punctures within 1 year of clinical MRI scans. We first analysed neurodegeneration patterns across four biomarker groups: 60 controls (A-T-&CU; amyloid negative, tau negative, cognitively unimpaired), 25 A+T- (amyloid positive, tau negative), 121 A+T+ (amyloid positive, tau positive) and 100 other dementia (A-T-&CI; amyloid negative, tau negative, cognitively impaired). Second, we examined volumetric associations with amyloid (amyloid positive, tau negative versus control) and tau in the presence of amyloid (amyloid positive, tau positive versus amyloid positive, tau negative) across 52 brain areas. Third, we examined sex differences in these relationships. Finally, we validated core analyses across three independent datasets-NACC (National Alzheimer's Coordinating Center), ADNI (Alzheimer's Disease Neuroimaging Initiative) and EPAD (European Prevention of Alzheimer's Dementia)-totalling 3137 participants, and performed meta-analyses to obtain more robust estimates. We observed distinct neurodegeneration patterns across biomarker groups, with disrupted connectivity (brain volume covariance networks) in amyloid positive and other dementia groups, while amyloid and tau negative, cognitively unimpaired controls exhibited the most connected network. Amyloid was associated with subcortical, cerebellar and brainstem atrophy, with consistent association observations in the thalamus and amygdala across all four datasets. Tau in the presence of amyloid demonstrated general brain shrinkage through enlargement of extracerebral CSF, alongside unexpected ventricle shrinkages. Sex-based analyses revealed that A+T+ (amyloid positive, tau positive) had lower sex differences in connectivity patterns compared with other groups. Sex differences were also noted in amyloid-related ventricular volume changes. This study reveals how amyloid and tau affect brain connectivity and volume across sex and CSF biomarker groups, emphasizing global brain changes and sex differences. By leveraging automated pipelines and advanced MRI and biomarker analyses, we extracted meaningful and replicable findings from heterogeneous clinical samples from real-world data. The meta-analyses across four datasets enhance the generalizability of our results.

摘要

阿尔茨海默病脑脊液(CSF)生物标志物与神经退行性变效应之间的关系尚未完全明确。本研究在一个临床神经学样本中,调查了不同CSF阿尔茨海默病生物标志物组的神经退行性变模式、脑容量与CSF淀粉样蛋白和tau蛋白状态的关联以及这些关系中的性别差异。对麻省总医院布莱根医疗系统中306名年龄在50岁以上(平均年龄 = 68.4 ± 8.8岁;43.1%为女性)的患者进行了MRI和CSF阿尔茨海默病生物标志物数据的分析,这些患者在临床MRI扫描后1年内接受了腰椎穿刺。我们首先分析了四个生物标志物组的神经退行性变模式:60名对照者(A-T-&CU;淀粉样蛋白阴性、tau蛋白阴性、认知未受损)、25名A+T-(淀粉样蛋白阳性、tau蛋白阴性)、121名A+T+(淀粉样蛋白阳性、tau蛋白阳性)和100名其他痴呆患者(A-T-&CI;淀粉样蛋白阴性、tau蛋白阴性、认知受损)。其次,我们在52个脑区检查了淀粉样蛋白(淀粉样蛋白阳性、tau蛋白阴性与对照)以及存在淀粉样蛋白时tau蛋白(淀粉样蛋白阳性、tau蛋白阳性与淀粉样蛋白阳性、tau蛋白阴性)与脑容量的关联。第三,我们研究了这些关系中的性别差异。最后,我们在三个独立数据集——NACC(国家阿尔茨海默病协调中心)、ADNI(阿尔茨海默病神经影像学倡议)和EPAD(欧洲预防阿尔茨海默病痴呆症)——中对核心分析进行了验证,这三个数据集共有3137名参与者,并进行了荟萃分析以获得更可靠的估计。我们观察到不同生物标志物组存在明显的神经退行性变模式,淀粉样蛋白阳性组和其他痴呆组的连接性(脑容量协方差网络)受到破坏,而淀粉样蛋白和tau蛋白均为阴性、认知未受损的对照组表现出连接性最强的网络。淀粉样蛋白与皮质下、小脑和脑干萎缩相关,在所有四个数据集中丘脑和杏仁核均观察到一致的关联。存在淀粉样蛋白时,tau蛋白通过脑外CSF扩大导致全脑萎缩,同时脑室出现意外缩小。基于性别的分析显示,与其他组相比,A+T+(淀粉样蛋白阳性、tau蛋白阳性)在连接模式上的性别差异较小。在淀粉样蛋白相关的脑室容积变化中也注意到了性别差异。本研究揭示了淀粉样蛋白和tau蛋白如何影响不同性别和CSF生物标志物组的脑连接性和脑容量,强调了全脑变化和性别差异。通过利用自动化流程以及先进的MRI和生物标志物分析技术,我们从真实世界数据的异质性临床样本中提取了有意义且可重复的发现。对四个数据集进行的荟萃分析提高了我们结果的普遍性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/978a/12152538/53aca9eb6d89/fcaf210f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/978a/12152538/bd990edae38b/fcaf210_ga.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/978a/12152538/94c5f64357bc/fcaf210f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/978a/12152538/62e37a019c6f/fcaf210f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/978a/12152538/a05db8624dd3/fcaf210f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/978a/12152538/ebeb0443ce82/fcaf210f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/978a/12152538/80904bb2560a/fcaf210f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/978a/12152538/53aca9eb6d89/fcaf210f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/978a/12152538/bd990edae38b/fcaf210_ga.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/978a/12152538/94c5f64357bc/fcaf210f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/978a/12152538/62e37a019c6f/fcaf210f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/978a/12152538/a05db8624dd3/fcaf210f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/978a/12152538/ebeb0443ce82/fcaf210f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/978a/12152538/80904bb2560a/fcaf210f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/978a/12152538/53aca9eb6d89/fcaf210f6.jpg

相似文献

1
Brain MRI signatures across sex and CSF Alzheimer's disease biomarkers.跨性别脑磁共振成像特征与脑脊液阿尔茨海默病生物标志物
Brain Commun. 2025 May 30;7(3):fcaf210. doi: 10.1093/braincomms/fcaf210. eCollection 2025.
2
The CSF p-tau/β-amyloid 42 ratio correlates with brain structure and fibrillary β-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer's disease.在临床前阿尔茨海默病的最早阶段,脑脊液中磷酸化tau蛋白与β淀粉样蛋白42的比值与认知未受损个体的脑结构和纤维状β淀粉样蛋白沉积相关。
Brain Commun. 2024 Dec 13;7(1):fcae451. doi: 10.1093/braincomms/fcae451. eCollection 2025.
3
Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.与临床前阿尔茨海默病核心 CSF 生物标志物相关的纵向结构脑变化:两项独立数据集研究。
Neuroimage Clin. 2018 Apr 16;19:190-201. doi: 10.1016/j.nicl.2018.04.016. eCollection 2018.
4
Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.血液磷酸化 tau 181 作为阿尔茨海默病的生物标志物:使用来自四个前瞻性队列的数据进行的诊断性能和预测模型研究。
Lancet Neurol. 2020 May;19(5):422-433. doi: 10.1016/S1474-4422(20)30071-5.
5
Brain alterations in the early Alzheimer's continuum with amyloid-β, tau, glial and neurodegeneration CSF markers.早期阿尔茨海默病连续体中伴有淀粉样蛋白-β、tau蛋白、神经胶质和神经退行性变脑脊液标志物的脑改变。
Brain Commun. 2022 May 24;4(3):fcac134. doi: 10.1093/braincomms/fcac134. eCollection 2022.
6
Comparison of different MRI-based morphometric estimates for defining neurodegeneration across the Alzheimer's disease continuum.比较基于 MRI 的不同形态计量学估计值在阿尔茨海默病连续体中定义神经退行性变的作用。
Neuroimage Clin. 2019;23:101895. doi: 10.1016/j.nicl.2019.101895. Epub 2019 Jun 10.
7
Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.血浆神经丝轻链与阿尔茨海默病影像学生物标志物的阶段特异性关联。
Brain. 2020 Dec 1;143(12):3793-3804. doi: 10.1093/brain/awaa342.
8
ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.载脂蛋白E4对轻度认知障碍和阿尔茨海默病自动诊断分类器的影响。
Neuroimage Clin. 2014 Jan 4;4:461-72. doi: 10.1016/j.nicl.2013.12.012. eCollection 2014.
9
2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.阿尔茨海默病神经影像学计划2014年更新:自启动以来发表论文综述
Alzheimers Dement. 2015 Jun;11(6):e1-120. doi: 10.1016/j.jalz.2014.11.001.
10
Proteomic clusters underlie heterogeneity in preclinical Alzheimer's disease progression.蛋白质组簇是临床前阿尔茨海默病进展异质性的基础。
Brain. 2023 Jul 3;146(7):2944-2956. doi: 10.1093/brain/awac484.

本文引用的文献

1
A network correspondence toolbox for quantitative evaluation of novel neuroimaging results.一种用于定量评估新型神经影像学结果的网络通信工具箱。
Nat Commun. 2025 Mar 25;16(1):2930. doi: 10.1038/s41467-025-58176-9.
2
Sex/gender effects of glial reactivity on preclinical Alzheimer's disease pathology.神经胶质细胞反应性对临床前阿尔茨海默病病理学的性别影响。
Mol Psychiatry. 2025 Apr;30(4):1430-1439. doi: 10.1038/s41380-024-02753-9. Epub 2024 Oct 9.
3
Predicting Brain Amyloid Status Using the National Institute of Health Toolbox (NIHTB) for Assessment of Neurological and Behavioral Function.
利用国立卫生研究院神经行为功能评估工具包(NIHTB)预测大脑淀粉样蛋白状态。
J Prev Alzheimers Dis. 2024;11(4):943-957. doi: 10.14283/jpad.2024.77.
4
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup.修订的阿尔茨海默病诊断和分期标准:阿尔茨海默病协会工作组。
Alzheimers Dement. 2024 Aug;20(8):5143-5169. doi: 10.1002/alz.13859. Epub 2024 Jun 27.
5
2024 Alzheimer's disease facts and figures.2024 年阿尔茨海默病事实和数据。
Alzheimers Dement. 2024 May;20(5):3708-3821. doi: 10.1002/alz.13809. Epub 2024 Apr 30.
6
Association of CSF biomarkers with MRI brain changes in Alzheimer's disease.脑脊液生物标志物与阿尔茨海默病脑磁共振成像改变的关联
Alzheimers Dement (Amst). 2024 Feb 23;16(1):e12556. doi: 10.1002/dad2.12556. eCollection 2024 Jan-Mar.
7
Cerebrospinal fluid biomarker profiling of diverse pathophysiological domains in Alzheimer's disease.阿尔茨海默病不同病理生理领域的脑脊液生物标志物分析
Alzheimers Dement (N Y). 2024 Jan 24;10(1):e12440. doi: 10.1002/trc2.12440. eCollection 2024 Jan-Mar.
8
Thalamic nuclei changes in early and late onset Alzheimer's disease.早发性和晚发性阿尔茨海默病中的丘脑核变化
Curr Res Neurobiol. 2023 Mar 24;4:100084. doi: 10.1016/j.crneur.2023.100084. eCollection 2023.
9
Gray matter network properties show distinct associations with CSF p-tau 181 levels and amyloid status in individuals without dementia.在无痴呆症个体中,灰质网络特性与脑脊液磷酸化tau蛋白181水平及淀粉样蛋白状态呈现出不同的关联。
Aging Brain. 2022 Oct 23;2:100054. doi: 10.1016/j.nbas.2022.100054. eCollection 2022.
10
Robust machine learning segmentation for large-scale analysis of heterogeneous clinical brain MRI datasets.用于大规模分析异质临床脑 MRI 数据集的稳健机器学习分割。
Proc Natl Acad Sci U S A. 2023 Feb 28;120(9):e2216399120. doi: 10.1073/pnas.2216399120. Epub 2023 Feb 21.